These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The relationship between sex hormones, the vaginal microbiome and immunity in HIV-1 susceptibility in women. Wessels JM; Felker AM; Dupont HA; Kaushic C Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30154116 [TBL] [Abstract][Full Text] [Related]
26. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369 [TBL] [Abstract][Full Text] [Related]
27. Hormonal contraception and the risk of HIV acquisition among women in South Africa. Morrison CS; Skoler-Karpoff S; Kwok C; Chen PL; van de Wijgert J; Gehret-Plagianos M; Patel S; Ahmed K; Ramjee G; Friedland B; Lahteenmaki P AIDS; 2012 Feb; 26(4):497-504. PubMed ID: 22156973 [TBL] [Abstract][Full Text] [Related]
28. Long-acting hormonal contraceptives for women. Garza-Flores J; Hall PE; Perez-Palacios G J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567 [TBL] [Abstract][Full Text] [Related]
29. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice. Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113 [TBL] [Abstract][Full Text] [Related]
30. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Myer L; Denny L; Wright TC; Kuhn L Int J Epidemiol; 2007 Feb; 36(1):166-74. PubMed ID: 17175547 [TBL] [Abstract][Full Text] [Related]
31. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. Mitchell CM; McLemore L; Westerberg K; Astronomo R; Smythe K; Gardella C; Mack M; Magaret A; Patton D; Agnew K; McElrath MJ; Hladik F; Eschenbach D J Infect Dis; 2014 Aug; 210(4):651-5. PubMed ID: 24652495 [TBL] [Abstract][Full Text] [Related]
32. Contraceptive effects on the cervicovaginal microbiome: Recent evidence including randomized trials. Balle C; Happel AU; Heffron R; Jaspan HB Am J Reprod Immunol; 2023 Nov; 90(5):e13785. PubMed ID: 37881121 [TBL] [Abstract][Full Text] [Related]
33. Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. Roxby AC; Fredricks DN; Odem-Davis K; Ásbjörnsdóttir K; Masese L; Fiedler TL; De Rosa S; Jaoko W; Kiarie JN; Overbaugh J; McClelland RS J Acquir Immune Defic Syndr; 2016 Apr; 71(4):359-66. PubMed ID: 26914908 [TBL] [Abstract][Full Text] [Related]
34. Association of endogenous progesterone levels in young women using hormonal contraception with recent HIV-1 infection. Boodhram R; Moodley D; Abbai N; Ramjee G BMC Womens Health; 2019 May; 19(1):63. PubMed ID: 31068152 [TBL] [Abstract][Full Text] [Related]
35. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913 [TBL] [Abstract][Full Text] [Related]
36. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Mostad SB; Overbaugh J; DeVange DM; Welch MJ; Chohan B; Mandaliya K; Nyange P; Martin HL; Ndinya-Achola J; Bwayo JJ; Kreiss JK Lancet; 1997 Sep; 350(9082):922-7. PubMed ID: 9314871 [TBL] [Abstract][Full Text] [Related]